p73 and p63 regulate the expression of fibroblast growth factor receptor 3

Biochemical and Biophysical Research Communications

Volumn 394, Issue 3, 2010, Pages 824-828

  Sayan, A Emre ^a,b   D'Angelo, Barbara ^a,c   Sayan, Berna S ^a   Tucci, Paola ^a,d   Cimini, AnnaMaria ^c   Cerù, Maria Paola ^c   Knight, Richard A ^a   Melino, Gerry ^a,d  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Apoptosis; Bladder cancer; Cell death; FGFR3; p63; p73

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P63; PROTEIN P73; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER INVASION; CELL DEATH; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; RNA INTERFERENCE; SEQUENCE ALIGNMENT; SUPERFICIAL CANCER;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SKIN NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 77950469694     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.084     Document Type: Article

References (39)

1. Deyoung M.P., and Ellisen L.W. P63 and p73 in human cancer: defining the network. Oncogene 26 (2007) 5169-5183
2. Vousden K.H., and Lane D.P. P53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283
3. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C., and McKeon F. P63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398 (1999) 714-718
4. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., and Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404 (2000) 99-103
5. Melino G., De Laurenzi V., and Vousden K.H. P73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2 (2002) 605-615
6. Grob T.J., Novak U., Maisse C., Barcaroli D., Luthi A.U., Pirnia F., Hugli B., Graber H.U., De Laurenzi V., Fey M.F., Melino G., and Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8 (2001) 1213-1223
7. Ghioni P., Bolognese F., Duijf P.H., Van Bokhoven H., Mantovani R., and Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol. Cell. Biol. 22 (2002) 8659-8668
8. Candi E., Rufini A., Terrinoni A., Dinsdale D., Ranalli M., Paradisi A., De Laurenzi V., Spagnoli L.G., Catani M.V., Ramadan S., Knight R.A., and Melino G. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ. 13 (2006) 1037-1047
9. De Laurenzi V., Costanzo A., Barcaroli D., Terrinoni A., Falco M., Annicchiarico-Petruzzelli M., Levrero M., and Melino G. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J. Exp. Med. 188 (1998) 1763-1768
10. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., and McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2 (1998) 305-316
11. Turner N., and Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10 (2010) 116-129
12. Ornitz D.M., and Marie P.J. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 16 (2002) 1446-1465
13. Eswarakumar V.P., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16 (2005) 139-149
14. Knowles M.A. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J. Urol. 25 (2007) 581-593
15. Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., Gasc J.M., Jorcano J., Werner S., Sastre-Garau X., Thiery J.P., and Radvanyi F. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet. 14 (2005) 1153-1160
16. Bernard-Pierrot I., Brams A., Dunois-Larde C., Caillault A., Diez de Medina S.G., Cappellen D., Graff G., Thiery J.P., Chopin D., Ricol D., and Radvanyi F. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27 (2006) 740-747
17. Sayan A.E., Griffiths T.R., Pal R., Browne G.J., Ruddick A., Yagci T., Edwards R., Mayer N.J., Qazi H., Goyal S., Fernandez S., Straatman K., Jones G.D., Bowman K.J., Colquhoun A., Mellon J.K., Kriajevska M., and Tulchinsky E. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc. Natl. Acad. Sci. USA 106 (2009) 14884-14889
18. Sayan A.E., Paradisi A., Vojtesek B., Knight R.A., Melino G., and Candi E. New antibodies recognizing p73: comparison with commercial antibodies. Biochem. Biophys. Res. Commun. 330 (2005) 186-193
19. Nakano K., Balint E., Ashcroft M., and Vousden K.H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19 (2000) 4283-4289
20. Sayan B.S., Yang A.L., Conforti F., Bernardini S., Tucci P., Vasa-Nicotera M., Knight R.A., and Melino G. Induction of TAp63 by histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 391 (2010) 1748-1751
21. Yu K., Xu J., Liu Z., Sosic D., Shao J., Olson E.N., Towler D.A., and Ornitz D.M. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 130 (2003) 3063-3074
22. Colvin J.S., Bohne B.A., Harding G.W., McEwen D.G., and Ornitz D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet. 12 (1996) 390-397
23. Ornitz D.M., and Itoh N. Fibroblast growth factors. Genome Biol. 2 (2001) REVIEWS3005
24. Tomasini R., Tsuchihara K., Wilhelm M., Fujitani M., Rufini A., Cheung C.C., Khan F., Itie-Youten A., Wakeham A., Tsao M.S., Iovanna J.L., Squire J., Jurisica I., Kaplan D., Melino G., Jurisicova A., and Mak T.W. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22 (2008) 2677-2691
25. Di Como C.J., Urist M.J., Babayan I., Drobnjak M., Hedvat C.V., Teruya-Feldstein J., Pohar K., Hoos A., and Cordon-Cardo C. P63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8 (2002) 494-501
26. Tomlinson D.C., Baldo O., Harnden P., and Knowles M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213 (2007) 91-98
27. Puig P., Capodieci P., Drobnjak M., Verbel D., Prives C., Cordon-Cardo C., and Di Como C.J. p73 expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin. Cancer Res. 9 (2003) 5642-5651
28. L'Hote C.G., and Knowles M.A. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp. Cell Res. 304 (2005) 417-431
29. Jebar A.H., Hurst C.D., Tomlinson D.C., Johnston C., Taylor C.F., and Knowles M.A. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24 (2005) 5218-5225
30. Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K., McGowan S.J., Pfeifer S.P., McVean G.A., Meyts E.R., and Wilkie A.O. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat. Genet. 41 (2009) 1247-1252
31. Memon A.A., Sorensen B.S., Meldgaard P., Fokdal L., Thykjaer T., and Nexo E. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br. J. Cancer 94 (2006) 1703-1709
32. Savagner P., Valles A.M., Jouanneau J., Yamada K.M., and Thiery J.P. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol. Biol. Cell 5 (1994) 851-862
33. Candi E., Rufini A., Terrinoni A., Giamboi-Miraglia A., Lena A.M., Mantovani R., Knight R., and Melino G. DeltaNp63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proc. Natl. Acad. Sci. USA 104 (2007) 11999-12004
34. Tomlinson D.C., L'Hote C.G., Kennedy W., Pitt E., and Knowles M.A. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res. 65 (2005) 10441-10449
35. Tomasini R., Tsuchihara K., Tsuda C., Lau S.K., Wilhelm M., Ruffini A., Tsao M.S., Iovanna J.L., Jurisicova A., Melino G., and Mak T.W. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc. Natl. Acad. Sci. USA 106 (2009) 797-802
36. Wilhelm M.T., Rufini A., Wetzel M.K., Tsuchihara K., Inoue S., Tomasini R., Itie-Youten A., Wakeham A., Arsenian-Henriksson M., Melino G., Kaplan D.R., Miller F.D., and Mak T.W. Isoform-specific p73 knockout mice reveal a novel role for {Delta}Np73 in the DNA damage response pathway. Genes Dev. 24 (2010) 549-560
37. Browne G., Sayan A.E., and Tulchinsky E. ZEB proteins link cell motility with cell cycle control and cell survival in cancer. Cell Cycle 9 (2010) 886-891
38. Sayan B.S., Sayan A.E., Yang A.L., Aqeilan R.I., Candi E., Cohen G.M., Knight R.A., Croce C.M., and Melino G. Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. Proc. Natl. Acad. Sci. USA 104 (2007) 10871-10876
39. Tsunoda T., and Takagi T. Estimating transcription factor bindability on DNA. Bioinformatics 15 (1999) 622-630